Investigating how a specific protein modification affects breast cancer behavior
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · NIH-11211983
This study is looking at how a protein called MnSOD affects the way estrogen receptor-positive breast cancer cells grow and respond to treatment, which could help find new ways to fight this type of cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER (nih funded) |
| Locations | 1 site (SAN ANTONIO, UNITED STATES) |
| Trial ID | NIH-11211983 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how changes in a protein called manganese superoxide dismutase (MnSOD) influence the metabolism of estrogen receptor-positive breast cancer cells. By examining how the acetylation of MnSOD affects the levels of reactive oxygen species (ROS) in these cells, the study aims to uncover mechanisms that lead to tumor growth and resistance to common therapies. The researchers will analyze the impact of these changes on cancer cell behavior, particularly regarding their ability to adapt and resist treatment. This could provide insights into new therapeutic strategies for patients with this type of breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with estrogen receptor-positive breast cancer, particularly those who have experienced treatment resistance.
Not a fit: Patients with other types of breast cancer or those who have not been diagnosed with breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve outcomes for patients with estrogen receptor-positive breast cancer.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways in cancer, suggesting that this approach may yield significant insights.
Where this research is happening
SAN ANTONIO, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCIENCE CENTER — SAN ANTONIO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GIUS, DAVID — UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
- Study coordinator: GIUS, DAVID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer